Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| D9612L00048 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A study to look at the rates of remission (non re-appearance of erosive esomeprazole) when treated with esomeprazole or lansoprazole; in patients in with erosive esomeprazole (EE) that is in remission (i.e. previously healed EE).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Nexium |
|
| 2 | Active Comparator | Prevacid |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Esomeprazole | Drug |
|
| |
| Lansoprazole |
| Measure | Description | Time Frame |
|---|---|---|
| To compare rates of remission (non re-appearance of erosive esomeprazole) when treated with esomeprazole or lansoprazole; in patients in with erosive esomeprazole (EE) that is in remission (i.e. previously healed EE). | Symptoms will be assessed by the investigator at each visit and the patients will undergo an endoscopy at Months 3 and 6 |
| Measure | Description | Time Frame |
|---|---|---|
| To compare endoscopic remission rates through 6 months of treatment with E20 and L15, after initial healing of EE. | Symptoms will be assessed by the investigator at each visit and the patients will undergo an endoscopy at Months 3 and 6 | |
| The assessment of symptoms in the two treatment groups after 1, 3 and 6 months. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Paula Fernstrom | Nexium Global Product Director, AstraZeneca | Study Director |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
|
| patients will undergo an endoscopy at Months 3 and 6 |
| To assess the safety and tolerability of up to 6 months of treatment with E20 and L15 after initial healing of EE. | Symptoms will be assessed by the investigator at each visit and the patients will undergo an endoscopy at Months 3 and 6 |
| ID | Term |
|---|---|
| D006356 | Heartburn |
| ID | Term |
|---|---|
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D064098 | Esomeprazole |
| D064747 | Lansoprazole |
| ID | Term |
|---|---|
| D009853 | Omeprazole |
| D053799 | 2-Pyridinylmethylsulfinylbenzimidazoles |
| D013454 | Sulfoxides |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D011725 | Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D001562 | Benzimidazoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided